CHINA PHARMA HOLDINGS, INC. Repayments of Long-term Lines of Credit
CHINA PHARMA HOLDINGS, INC. (CPHI) reported Repayments of Long-term Lines of Credit of CNY 1.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-01.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermLinesOfCredit · last filed 2026-04-01
- CHINA PHARMA HOLDINGS, INC. repayments of long-term lines of credit for the quarter ending 2025-12-31 was 0.00 CNY.
- CHINA PHARMA HOLDINGS, INC. repayments of long-term lines of credit for the quarter ending 2025-09-30 was 551.25K CNY.
- CHINA PHARMA HOLDINGS, INC. repayments of long-term lines of credit for the quarter ending 2025-06-30 was 0.00 CNY.
- CHINA PHARMA HOLDINGS, INC. repayments of long-term lines of credit for the quarter ending 2025-03-31 was 551.25K CNY.
- CHINA PHARMA HOLDINGS, INC. repayments of long-term lines of credit for fiscal 2025 was 1.10M CNY.
CNY
| Period end | Repayments of Long-term Lines of Credit | Repayments of Long-term Lines of Credit 3 month | Repayments of Long-term Lines of Credit 6 month | Repayments of Long-term Lines of Credit 9 month | Repayments of Long-term Lines of Credit 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | 0.00 CNY derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | 551.25K CNY derived: sum of 2 quarters · filed 2026-04-01 | 551.25K CNY derived: sum of 3 quarters · filed 2026-04-01 | 1.10M CNY 10-K · filed 2026-04-01 | |
| 2025-09-30 | 551.25K CNY derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 551.25K CNY derived: sum of 2 quarters · filed 2025-11-12 | 1.10M CNY 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | 0.00 CNY derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 551.25K CNY 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | 551.25K CNY 10-Q · filed 2025-05-14 | ||||
| 2024-12-02 | 3.50M CNY 10-K · filed 2026-04-01 |
USD
| Period end | Repayments of Long-term Lines of Credit 3 month | Repayments of Long-term Lines of Credit 6 month | Repayments of Long-term Lines of Credit 9 month | Repayments of Long-term Lines of Credit 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $76.50K derived: sum of 2 quarters · filed 2026-04-01 | $76.00K derived: sum of 3 quarters · filed 2026-04-01 | $153.00K 10-K · filed 2026-04-01 |
| 2025-09-30 | $76.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $76.00K derived: sum of 2 quarters · filed 2025-11-12 | $153.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$500.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $76.50K 10-Q · filed 2025-08-14 | ||
| 2025-03-31 | $77.00K 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |